Table 2.
In vitro Inhibitory assessment of the promising sulfonamide-based derivatives 4, 7 and 9 against VEGFR-2 and carbonic anhydrase isoforms hCA IX and hCA XII comparing with sorafenib and SLC-0111, respectively.
| Compound No | IC50 (mean ± SD) | ||
|---|---|---|---|
| VEGFR-2 (µM) | Carbonic anhydrase isoforms (nM) | ||
| hCA IX | hCA XII | ||
| 4 | 181 ± 0.66 | 142 | 35.9 |
| 7 | 1.33 ± 0.10 | 66 | 7.6 |
| 9 | 0.38 ± 0.14 | 40 | 3.2 |
| Sorafenib | 0.43 ± 0.10 | – | – |
| SLC-0111 | – | 53 | 4.8 |
IC50 Compound concentration necessary to inhibit the enzyme activity by 50%, SD Standard deviation, each value is the mean of three values, (–) not detected.